Westwood%2c Los Angeles, CANCT06326411Now EnrollingIRB Ready

Oncology Clinical Trial in Westwood%2c Los Angeles, CA

Access cutting-edge oncology treatment through this clinical trial at a research site in Westwood%2c Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Nested Therapeutics, Inc

Quick Self-Assessment

See if you qualify for this Westwood%2c Los Angeles location

Preparing your pre-screening questions…

Expert Care in Westwood%2c Los Angeles

Access oncology specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related oncology treatment provided free

Apply for This Westwood%2c Los Angeles Location

Check if you qualify for this oncology clinical trial in Westwood%2c Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Westwood%2c Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Westwood%2c Los Angeles site if eligible
  4. 4Begin participation

About This Oncology Study in Westwood%2c Los Angeles

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

Sponsor: Nested Therapeutics, Inc

Who Can Participate

Inclusion Criteria

Subjects are eligible to be included in the study only if all of the following criteria apply:
Subjects must be ≥18 years old (or of legal age of consent in the country in which the study is taking place) at the time of signing the informed consent.
Subjects who have a histologically or cytologically documented metastatic or locally advanced solid tumor, for which standard of care (SoC) therapy does not exist, no longer provides benefit, or is not tolerated by the subject, or the subject has been assessed by the Investigator as not being suitable for SoC therapy.
Part A: Subjects with any solid tumor with genetic alteration of or evidence of tumor dependence upon the RAS/MAPK pathway (subject to additional restrictions specified in the study protocol)
Part B: Subjects must be diagnosed with one of the following solid tumors harboring specified genetic alterations based on a validated local test: i. Melanoma Cohorts:
Activating NRAS mutations
Select BRAF alterations ii. Non-Melanoma Cohorts:
Solid tumors with NRAS activating mutations
Solid tumors with KRAS activating mutations
Solid tumors with select BRAF alterations
Glioma with BRAF alterations
Newly obtained or archived tumor tissue is required
Part B: measurable disease as defined by RECIST Version 1.1 or by other disease assessment tool standard for a given tumor type (if RECIST v. 1.1 is not standard)
Performance status
Solid tumors other than glioma: ECOG 0 or 1
Glioma: Karnofsky ≥ 70 and ECOG 0 or 1
Have adequate organ function
Understand and voluntarily sign an Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to any study-specific evaluation.
Life expectancy ≥ 12 weeks

Exclusion Criteria

Subjects are excluded from the study if any of the following criteria apply:
Conditions interfering with oral intake of NST-628
Conditions interfering with intestinal absorption of an orally administered drug
A history or current evidence of significant retinal pathology leading to increased risk of RVO
A history or evidence of cardiovascular risk
Current or history within 6 months of planned Cycle 1 Day 1 of pneumonitis or interstitial lung disease (ILD)
Part B: prior treatment with any MEK or BRAF inhibitor
Untreated or symptomatic central nervous system (CNS) metastases
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Targeted small molecule agents within 14 days or 5 half-lives of Cycle 1 Day 1
Females who are pregnant or breastfeeding.
For fertile patients (female able to become pregnant or male able to father a child), refusal to use effective contraception during the period of the trial and for 6 months after the last dose of NST-628
Presence of any serious or unstable concomitant systemic disorder incompatible with the clinical study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Westwood%2c Los Angeles?

Yes, this clinical trial (NCT06326411) has an active research site in Westwood%2c Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Oncology Treatment Options in Westwood%2c Los Angeles, CA

If you're searching for oncology treatment options in Westwood%2c Los Angeles, CA, this clinical trial (NCT06326411) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Westwood%2c Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced oncology specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all oncology clinical trials near you to find additional studies recruiting in your area.

More Pediatric Cancer Trials in Westwood%2c Los Angeles, CA

See all pediatric cancer clinical trials recruiting in Westwood%2c Los Angeles — not just this study.

Browse Pediatric Cancer Trials in Westwood%2c Los Angeles →

Browse More Trials by Condition

Pediatric Cancer TrialsAll Conditions →

Ready to Join in Westwood%2c Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Westwood%2c Los Angeles, CA